

Patient: [REDACTED]  
DOB: [REDACTED] Age: 43 Gender: F  
Patient Identifiers: [REDACTED]  
Visit Number (FIN): [REDACTED]

Client: [REDACTED]  
Physician: [REDACTED]

ARUP Test Code: 2002294  
Collection Date: 04/27/2018  
Received in lab: 04/27/2018  
Completion Date: 05/01/2018

**Interpretation**

Specimen Received  
Specimen Type: Bone Marrow (CD138+)  
Reason for Referral: MGUS  
Test Performed: FISH MM Panel

**ABNORMAL FISH RESULT**  
t(11;14)(q13;q32) (CCND1;IGH): translocation present

**NORMAL FISH RESULTS**  
1q21 (CKS1B): gain not detected  
9q34 (ASS1): gain not detected  
11q13 (CCND1): gain not detected  
15q24 (PML): gain not detected  
17p13 (TP53): deletion not detected

**DIAGNOSTIC IMPRESSION:**  
Fluorescence in situ hybridization (FISH) analysis was performed with the MM panel probes: CKS1B, TP53 (Cytocell), ASS1, CCND1/IGH XT, IGH, and PML (Abbott Molecular) on CD138+ sorted cells (STEMCELL Technologies, Inc.). 200 interphase cells were scored for each probe combination.

This analysis showed evidence of a t(11;14)(q13;q32) resulting in a fusion of IGH and CCND1 in 153/200 (76.5 percent) cells scored.

FISH analysis with the remaining MM panel probes showed normal results with no evidence of gain of CKS1B at 1q, TP53 deletion, or gain of chromosomes 9, 11 or 15.

In multiple myeloma, t(11;14) in the absence of unfavorable risk genetics has been associated with a more favorable prognosis. Please correlate these results with clinical findings in this patient.

Reference:  
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.): WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon 2008.

ISCN:  
nuc ish(CKS1B,TP53)x2[200],  
(ASS1,PML)x2[200],  
(CCND1x3,IGHx3)(CCND1 con IGHx2)[153/200]



Patient: [REDACTED]  
ARUP Accession: 18-117-109357

# Multiple Myeloma Panel by FISH

Patient: [REDACTED] | Date of Birth: [REDACTED] | Gender: F | Physician: [REDACTED]  
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

This result has been reviewed and approved by Bo Hong, MD, FACMG  
Electronic Signature

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: [aruplab.com/CS](http://aruplab.com/CS)

